A few facts from the study along with the very basics — such as cost and harms of the intervention — would have improved this release.
The study results are unpublished making follow-up and verification impossible.
While the release provides good supporting data, readers should remember that the study was not blinded or placebo controlled which introduces some limitations.
More discussion on the potential cost savings would have rounded this release out nicely.
Short on details, long on promise for an alleged ‘breakthrough’ minimally invasive surgery for enlarged prostates.
The release does not address cost or potential harms, and does not make clear how this study builds on or differs from previous research.
This study may be of great interest to drug researchers, but its relevance to practicing clinicians and the general public remains unknown.
No where did the release suggest that seniors should check with their doctors before launching a new exercise program.
The release claims that the test results can differentiate between MS and non-MS, and between MS subtypes, but there are no numbers provided for us to assess that.
To the average reader, this device seems like a win-win for patients and medical institutions. Why not close the deal with some useful facts?